Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-234386
Filing Date
2026-05-21
Accepted
2026-05-21 16:02:18
Documents
66
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d845757d10q.htm   iXBRL 10-Q 1982181
2 EX-31.1 d845757dex311.htm EX-31.1 6731
3 EX-31.2 d845757dex312.htm EX-31.2 6710
4 EX-32.1 d845757dex321.htm EX-32.1 4507
5 EX-32.2 d845757dex322.htm EX-32.2 4495
  Complete submission text file 0001193125-26-234386.txt   6736905

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ck0002114044-20260331.xsd EX-101.SCH 945978
70 EXTRACTED XBRL INSTANCE DOCUMENT d845757d10q_htm.xml XML 885861
Mailing Address 101 MAIN STREET SUITE 1220 CAMBRIDGE MA 02142
Business Address 101 MAIN STREET SUITE 1220 CAMBRIDGE MA 02142 45 2138 7627
Hemab Therapeutics Holdings, Inc. (Filer) CIK: 0002114044 (see all company filings)

EIN.: 414241952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-43250 | Film No.: 261008256
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)